Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Sarepta Therapeutics, Inc. - Common Stock
(NQ:
SRPT
)
16.23
+0.14 (+0.87%)
Streaming Delayed Price
Updated: 4:00 PM EST, Mar 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sarepta Therapeutics, Inc. - Common Stock
< Previous
1
2
...
15
16
17
18
19
20
21
22
23
...
34
35
Next >
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
↗
October 18, 2024
The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma.
Via
Investor's Business Daily
2 High-Flying Growth Stocks With Massive Upside Potential
↗
October 17, 2024
These innovative drugmakers have potential catalysts ahead.
Via
The Motley Fool
Analyst Scoreboard: 12 Ratings For Sarepta Therapeutics
↗
October 04, 2024
Via
Benzinga
Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics
↗
October 03, 2024
These two could become direct competitors relatively soon.
Via
The Motley Fool
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 30, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Unveiling 26 Analyst Insights On Sarepta Therapeutics
↗
September 06, 2024
Via
Benzinga
How Is The Market Feeling About Sarepta Therapeutics?
↗
August 16, 2024
Via
Benzinga
A Closer Look at 28 Analyst Recommendations For Sarepta Therapeutics
↗
August 15, 2024
Via
Benzinga
Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher
September 30, 2024
Capricor Therapeutics Inc. (NASDAQ: CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like iomyopathy
Via
MarketBeat
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress
September 26, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
↗
September 18, 2024
Via
Benzinga
Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors
September 16, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
$100 Invested In This Stock 10 Years Ago Would Be Worth $600 Today
↗
August 12, 2024
Via
Benzinga
Smart Money Is Betting Big In SRPT Options
↗
August 08, 2024
Via
Benzinga
These 2 Biotech Stocks Are Set to Soar
↗
September 13, 2024
Innovative drugmakers developing treatments for conditions with high unmet needs can produce lucrative wins.
Via
The Motley Fool
Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year
September 05, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy
↗
September 03, 2024
Dyne Therapeutics revealed new clinical data from its Phase 1/2 DELIVER trial of DYNE-251 for Duchenne muscular dystrophy, showing significant increases in dystrophin expression and meaningful...
Via
Benzinga
Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Building
↗
September 03, 2024
The company is hoping to rival Sarepa's Exondys 51. But three executives just departed on what is calls "unprecedented" test results.
Via
Investor's Business Daily
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 30, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
August 30, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?
August 19, 2024
Avidity Biosciences' stock has performed incredibly well in 2024. Its Duchenne muscular dystrophy drug is showing strong results in trials.
Via
MarketBeat
2 Biotech Stocks to Buy Hand Over Fist in August
↗
August 12, 2024
Both of these biotechs are highly innovative companies.
Via
The Motley Fool
Warner Bros, Airbnb And Monster Beverage Are Among Top 10 Large Cap Losers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?
↗
August 11, 2024
These 10 stocks had the biggest drop last week, with McKesson Corporation, BIO-TECHNE Corp, and Warner Bros. Discovery, Inc. being the worst performers.
Via
Benzinga
How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics
↗
August 09, 2024
The company is coming up fast with a platform that could take on several of Sarepta's approved treatments.
Via
Investor's Business Daily
McKesson Reports Weak Sales, Joins JFrog, Fastly, Warner Bros. Discovery And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
↗
August 08, 2024
Via
Benzinga
7 Biotech Stocks to Buy for Their Game-Changing Potential
↗
August 08, 2024
Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks.
Via
InvestorPlace
Sarepta Therapeutics (SRPT) Q2 2024 Earnings Call Transcript
↗
August 08, 2024
SRPT earnings call for the period ending June 30, 2024.
Via
The Motley Fool
Topics
Earnings
SRPT Stock Earnings: Sarepta Therapeutics Beats EPS, Misses Revenue for Q2 2024
↗
August 07, 2024
SRPT stock results show that Sarepta Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Sarepta Therapeutics Announces Second Quarter 2024 Financial Results and Recent Corporate Developments
August 07, 2024
From
Sarepta Therapeutics, Inc.
Via
Business Wire
3 Genomics Stocks That May Transform Personalized Medicine
↗
August 06, 2024
These are three of the best genomics stocks to buy for a lucrative entry into a specialized section of the biotech industry.
Via
InvestorPlace
< Previous
1
2
...
15
16
17
18
19
20
21
22
23
...
34
35
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
